Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review

Antibodies to oxidized LDL (oxLDL) may be associated with improved outcomes in cardiovascular disease. However, analysis is restricted by heterogenous study design and endpoints. Our objective was to conduct a comprehensive systematic review assessing anti-oxLDL antibodies in relation to coronary artery disease (CAD). Through a systematic literature search, we identified all studies assessing the relationship of either, IgG or IgM ox-LDL/ copper-oxLDL/ malondialdehyde-LDL, with coronary atherosclerosis or cardiovascular events in populations with, and without, established CAD. Systematic review best practices were adhered to and study quality was assessed. An initial electronic database search identified 2059 records, which was subsequently followed by abstract and full-text review. Finally, we included 18 studies with over 1811 patients with CAD. The studies varied according to populations studied, conventional cardiovascular risk factors and interventional modalities used to assess CAD. IgM anti-oxLDL antibodies were found to indicate protection from more severe CAD and possibly cardiovascular events, whilst the relationship with IgG is more complex and difficult to elucidate, with studies reporting divergent results. In this systematic review, there is evidence that suggests a relationship between anti-oxLDL antibodies and CAD, especially for the IgM subclass. However, further studies, with well-characterized prospective cohorts, will be important to clarify these associations.

[1]  P. Serruys,et al.  IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3) , 2018, EBioMedicine.

[2]  C. Glass,et al.  Oxidized Phospholipids are Proinflammatory and Proatherogenic in Hypercholesterolemic Mice , 2018, Nature.

[3]  Jing Liu,et al.  Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies. , 2017, The Canadian journal of cardiology.

[4]  H. D. den Ruijter,et al.  High Levels of (Un)Switched Memory B Cells Are Associated With Better Outcome in Patients With Advanced Atherosclerotic Disease , 2017, Journal of the American Heart Association.

[5]  A. Khera,et al.  Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Demicco,et al.  Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. , 2017, Journal of the American College of Cardiology.

[7]  A. Hughes,et al.  High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial☆ , 2016, EBioMedicine.

[8]  B. Hedblad,et al.  Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[9]  O. Barbarash,et al.  Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction , 2014, Lipids in Health and Disease.

[10]  Evelyn Regar,et al.  In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. , 2014, European heart journal.

[11]  M. Ghayour-Mobarhan,et al.  Investigation of Serum Oxidized Low-Density Lipoprotein IgG Levels in Patients with Angiographically Defined Coronary Artery Disease , 2014, International journal of vascular medicine.

[12]  A. Frigo,et al.  Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. , 2013, International journal of cardiology.

[13]  M. M. Joosten,et al.  Oxidation-specific biomarkers and risk of peripheral artery disease. , 2013, Journal of the American College of Cardiology.

[14]  R. Virmani,et al.  Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions , 2012, Journal of Lipid Research.

[15]  Qingbo Xu,et al.  Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. , 2012, Journal of the American College of Cardiology.

[16]  P. Talmud,et al.  Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study , 2011, Journal of Lipid Research.

[17]  S. Reis,et al.  Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study , 2011, Journal of Lipid Research.

[18]  F. Tinahones,et al.  A higher level of IgM anti-oxidized LDL antibodies is associated with a lower severity of coronary atherosclerosis in patients on statins. , 2010, International journal of cardiology.

[19]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[20]  E. Brilakis,et al.  Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events Published, JLR Papers in Press, November 8, 2006. , 2007, Journal of Lipid Research.

[21]  P. Wilson,et al.  Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. , 2006, Atherosclerosis.

[22]  H. Sinzinger,et al.  Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. , 2006, British journal of clinical pharmacology.

[23]  H. Itabe,et al.  Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement , 2005, Neurological research.

[24]  A. Pessina,et al.  Antibodies to Oxidized Low-Density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients , 2003, Circulation.

[25]  H. Horiguchi,et al.  Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[26]  F. Werf,et al.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. , 1998, Circulation.

[27]  D. Haskard,et al.  Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy. , 2019, Trends in cardiovascular medicine.

[28]  Yilong Wang,et al.  Association of Oxidized Low-Density Lipoprotein With Prognosis of Stroke and Stroke Subtypes , 2017, Stroke.

[29]  R. Virmani,et al.  The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. , 2012, Cardiovascular revascularization medicine : including molecular interventions.

[30]  Tong Liu,et al.  Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. , 2011, Cardiology journal.

[31]  P. Luaces,et al.  Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease. , 2009, Human antibodies.

[32]  H. Ekmekçi,et al.  The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. , 2005, Clinical biochemistry.